Cross-State Prescribing of Schedule II Controlled Substances

Core Regulatory Requirements

Prescribers must check the Prescription Drug Monitoring Program (PDMP) in both the prescribing state and the patient's home state before writing Schedule II prescriptions, ideally before every prescription or at minimum every 3 months, as recommended by the American Medical Association, to identify all controlled substance prescriptions 2, 1
Many states lack data-sharing agreements between their PDMPs, creating significant gaps in identifying dangerous drug combinations or multiple prescribers when patients cross state lines, according to the American College of Emergency Physicians 3
When PDMP data reveals prescriptions from multiple states, calculate total morphine milligram equivalents (MME) per day across all prescriptions to assess cumulative overdose risk, as suggested by the Centers for Disease Control and Prevention 1

Review PDMPs from both states before each prescription to identify dangerous combinations or multiple prescribers, as recommended by the American Academy of Pain Medicine 1
Conduct urine drug testing before initiating therapy and at least annually, with more frequent testing for cross-state patients, as suggested by the American Society of Addiction Medicine 2, 1
A substance use disorder history is not an absolute contraindication but requires careful risk-benefit analysis considering current addiction treatment engagement, concurrent benzodiazepine use, total MME, and availability of non-opioid alternatives, according to the Substance Abuse and Mental Health Services Administration 1

Query the PDMP in your state AND the patient's home state to identify all controlled substance prescriptions, as recommended by the National Association of Boards of Pharmacy 2, 1
Calculate total daily MME if multiple opioid prescriptions are identified, as suggested by the Centers for Disease Control and Prevention 1
Use caution at ≥50 MME/day and avoid or carefully justify ≥90 MME/day, according to the American College of Physicians 4, 1

For patients with chronic pain traveling between states, nonpharmacologic and nonopioid pharmacologic therapies should be prioritized over opioids, as recommended by the American Academy of Pain Medicine 4
When opioids are necessary, establish realistic treatment goals for pain and function before initiating therapy and discuss discontinuation criteria if benefits don't outweigh risks, according to the American Society of Addiction Medicine 4, 5

Civil liability may occur if patient harm results from prescribing controlled substances across state lines without proper authorization, as noted by the American Bar Association 1